DoxyPEP Real-World Data Shows STI Rates Drop by Two-Thirds

There's a morning-after pill for STIs, and the first big real-world results out of the American South suggest it works just as well outside the lab. New data presented on August 24, 2026, at the AIDS 2026 conference in Rio de Janeiro shows that DoxyPEP — a single dose of the antibiotic doxycycline taken within three days of unprotected sex — cut overall STI rates by roughly two-thirds at a large clinic, matching the results of the landmark clinical trials. The finding matters because real-world evidence from the South has been scarce, and the benefit held up even for patients the original trials never studied.

DoxyPEP is short for doxycycline post-exposure prophylaxis. The regimen is straightforward: a 200-milligram dose of doxycycline taken within 72 hours of condomless sex, according to the U.S. Centers for Disease Control and Prevention, which issued formal DoxyPEP guidelines in June 2024. The CDC described it as the first new STI prevention tool in decades, a notable milestone given that rates of syphilis, gonorrhea, and chlamydia have been climbing for years. The prescription antibiotic is cheap, widely available, and already familiar to doctors who treat Lyme disease and acne — but until recently, no one knew whether the trial results would hold in ordinary clinic settings.

What the Duke clinic numbers actually show

The new analysis, led by Dr. Emily D. Niehaus, an infectious-diseases specialist at Duke University in Durham, North Carolina, looked back at 380 patients at an academic HIV clinic who were prescribed DoxyPEP between January 2022 and December 2025. About half were living with HIV and half were taking PrEP, with a median age of 36; the cohort was 95 percent men who have sex with men, and half were Black and 40 percent White, according to Medscape's reporting of the presentation.

Before the clinic started prescribing the antibiotic, the group logged 57 STI cases for every 100 person-years of follow-up. After DoxyPEP prescribing began, that figure dropped to 19 — a decline of about two-thirds (an incidence rate ratio of 0.33). Chlamydia cases fell the most sharply, down roughly four-fifths, while gonorrhea was cut in half and syphilis cases dropped from 10 to 2 per 100 person-years. Importantly, the decline was not simply a testing artifact: quarterly STI screening coverage stayed essentially flat, at about 60 percent before and 58 percent after among patients on PrEP, the researchers reported.

One of the most striking details is who benefited. The original randomized trials only enrolled people who had been diagnosed with a bacterial STI in the prior year. In the Duke cohort, nearly two-thirds of patients had no recent STI — and they saw essentially the same relative benefit as the higher-risk group. "These findings suggest that DoxyPEP may provide benefit across a broader range of risk profiles than those represented in original trials," Niehaus said, according to Medscape. That comparison could widen who clinics offer the drug to.

A four-year path from San Francisco to Rio

DoxyPEP's journey to the clinic moved fast. San Francisco's public health department became the first U.S. jurisdiction to issue doxyPEP guidance in October 2022, as summarized in a JAMA Internal Medicine article on the rollout. In 2023, a U.S. randomized trial funded by the National Institutes of Health found the antibiotic reduced STIs by about two-thirds — so decisively that the trial was stopped early — and the NIH highlighted the results in an agency news release. The CDC then formalized its guidelines in June 2024, recommending DoxyPEP for gay and bisexual men and transgender women with a recent STI history. The August 2026 Duke presentation is the latest milestone: confirmation that the protection survives contact with everyday clinical reality in a region where the epidemic hits hardest.

The NIH's account of the trial also explains why doctors took the idea seriously so quickly. In that study, participants in the standard-care group had quarterly STI incidence of 10.7 percent, versus 2.0 percent in the doxycycline group — the kind of gap that ends debates. The Virginia Department of Health now summarizes the CDC guidance for clinicians plainly: one 200-milligram dose within 72 hours of sex, no more than one dose per 24 hours.

The antibiotic resistance question won't go away

Enthusiasm comes with a real counterweight: antibiotic resistance. In the NIH-funded trial, 38.5 percent of gonorrhea samples from the DoxyPEP group showed tetracycline resistance, compared with 12.5 percent in standard care — though researchers cautioned that the number of cultures was small and needs follow-up, according to the NIH release. Gonorrhea has already outwitted a long list of antibiotics over the decades, which is why health authorities in Australia, the United Kingdom, and Germany have recommended against widespread doxyPEP adoption, the JAMA Internal Medicine article notes.

"This has long been the challenge with any preventive measure: How do you get in to the people who need it the most?" said Dr. Christopher Foltz of Cedars-Sinai, who was not involved in the study, in comments to Medscape. His point cuts both ways. The tool works, but reaching the young, high-risk populations who need it — and doing so without fueling resistance — is the harder half of the problem.

Why it matters for you

If you're sexually active, the practical takeaway is simple: a cheap, guideline-backed option now exists that wasn't on the menu a few years ago. DoxyPEP is already expanding beyond HIV specialty clinics into primary care, but awareness lags badly — most young adults who could benefit have never heard of it, and access varies widely by state, insurer, and clinic. The Duke data suggest the people who were excluded from the original trials may benefit just as much, which could push more clinicians to offer it proactively.

None of this replaces condoms or regular screening, and the resistance debate means prescribing should stay targeted rather than universal. But the trend line is clear: the first new STI prevention tool in a generation has now cleared the trial-to-real-world hurdle, and the next fight is making sure it reaches the people who need it most. Read more of our coverage on the Sexual Wellness beat and in Health.